Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

3.09
+0.13004.39%
Volume:2.62M
Turnover:7.86M
Market Cap:397.59M
PE:-2.28
High:3.11
Open:2.97
Low:2.88
Close:2.96
Loading ...

Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research

MT Newswires Live
·
06 Mar

Humacyte, Trestle Biotherapeutics announce research collaboration

TIPRANKS
·
06 Mar

Trestle Bio Announces Research Collaboration With Humacyte

THOMSON REUTERS
·
06 Mar

Trestle Bio Announces Research Collaboration with Humacyte

Business Wire
·
06 Mar

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

GlobeNewswire
·
03 Mar

Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System

MT Newswires Live
·
28 Feb

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess and Other Bioengineered Tissues

THOMSON REUTERS
·
27 Feb

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

GlobeNewswire
·
27 Feb

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Feb

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

GlobeNewswire
·
26 Feb

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Simply Wall St.
·
19 Feb

Humacyte, Pluristyx Announce Gene Editing Partnership

MT Newswires Live
·
29 Jan

Humacyte, Pluristyx announce expanded partnership

TIPRANKS
·
28 Jan

Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs

THOMSON REUTERS
·
28 Jan

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

GlobeNewswire
·
28 Jan

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Jan